Skin Cancer Screening: Why the German Government Wants to Restrict Current Preventive Screening
For years, skin cancer screening has been a fixed component of statutory cancer screening programmes in Germany. This nationwide service for the general population has now become a central issue in the current healthcare reform.
The German government is now pursuing the goal of restricting the existing skin cancer screening programme and focusing it more strongly on high-risk groups. The debate centres not only on questions regarding economic incentives for carrying out these costly examinations, but also on the considerable healthcare resources involved and whether this preventive service actually provides a meaningful benefit.
Skin Cancer Screening in Germany: How Does the Current Model Work?
The statutory skin cancer screening programme was introduced in 2008. Its aim was the earliest possible detection of skin cancer in asymptomatic individuals. Currently, insured persons aged 35 and older are (at the moment) entitled to an examination every two years — regardless of whether symptoms, suspicious skin changes or specific risk factors are present (Federal Joint Committee, 2023).
This makes Germany one of only a few countries in which nationwide skin cancer screening for asymptomatic individuals is a regular statutory health insurance benefit.
Healthcare Reform 2026: Why Does the German Government Want to Change Skin Cancer Screening?
As part of the healthcare reform, the FinanzKommission Gesundheit (“Financial Commission on Health”) recommended a fundamental restructuring of the current skin cancer screening programme.
The criticism focuses primarily on:
· the lack of robust evidence demonstrating a patient-relevant benefit
· the high costs of skin cancer screening
· the considerable consumption of medical resources
(Federal Ministry of Health, 2026).
The Federal Minister of Health has publicly adopted this position and announced plans to replace the current form of skin cancer screening with a more targeted approach. On 29 April 2026, the Federal Cabinet adopted the draft GKV-Beitragssatzstabilisierungsgesetzes (“Statutory Health Insurance Contribution Rate Stabilisation Act”), which explicitly includes the restructuring of skin cancer screening (Federal Ministry of Health, 2026).
System Burden: High Costs and Extensive Resource Allocation
The screening programme is performed millions of times every year — yet more examinations do not necessarily provide greater benefit for those examined!
In addition to the medical evaluation, the economic dimension also plays a central role. According to the Financial Commission, skin cancer screening generates annual costs of approx. €210 million — with an upward trend (Federal Ministry of Health, 2026).
The Commission also points out that the current model of skin cancer screening ties up considerable medical capacity. The report refers to several hundred full-time medical positions being occupied by the programme (Federal Ministry of Health, 2026).
This raises an increasingly important question: How meaningful is a screening programme performed millions of times each year if its actual benefit remains scientifically controversial?
Skin Cancer Screening: A Financially Attractive Model for Physicians
That’s because the current screening model is based on:
- millions of asymptomatic insured individuals
- regularly repeated examinations
- standardised reimbursable services
This creates high case numbers and stable revenue structures. Critics see this as a mechanism through which preventive programmes can become self-perpetuating — when/because medical benefit, economic interests and political expectations reinforce one another.
An International Comparison
Many countries do not operate comparable national screening programmes.
In the United States, for example, the United States Preventive Services Task Force concluded that current evidence is insufficient to determine the balance of benefits and harms of routine skin cancer screening in asymptomatic adults (USPSTF, 2023). Instead of nationwide screening, the US approach focuses more strongly on individual risk assessment and clinical judgement.
The United Kingdom likewise does not offer a general entitlement to population-wide skin cancer screening without clinical indication. The NHS primarily recommends awareness of suspicious skin changes and targeted diagnostic evaluation in suspected cases (Cancer Research UK).
Particularly interesting is the situation in Australia — a country with very high UV exposure and high skin cancer rates. Australia also does not have a nationwide skin cancer screening programme for asymptomatic individuals. Cancer Council Australia states that the evidence for population-wide screening remains insufficient. Instead, the strategy focuses more strongly on prevention, sun protection, public education and risk-based surveillance (Cancer Council Australia, 2019).
The international comparison therefore reveals a striking pattern: many countries with highly developed healthcare systems do not carry out general skin cancer screening for the entire population, but instead focus more heavily on high-risk groups, prevention and targeted diagnostics.
Conclusion: Prevention Matters — but an Excessive Approach Is Simply Expensive!
The current debate is not about whether skin cancer can be dangerous. Clearly, it can be. Dermatologists therefore emphasise the benefits that early detection may provide (Professional Association of German Dermatologists, 2026).
However, the current debate concerns the scale — including the financial scale — on which preventive measures should be implemented. Should they be applied universally and without specific indication? International comparisons appear to answer this question with a clear NO.
For many observers, the current reform plans represent part of a broader development within the healthcare system: healthcare services are no longer evaluated solely on whether they are available, but increasingly on whether their benefit justifies both their frequency of use and the burden they place on the healthcare system.
How these reforms will ultimately be implemented will likely become clear during the summer.
FAQ — Frequently Asked Questions About the Reform of Skin Cancer Screening
1. Who performs skin cancer screening and how is it carried out?
Skin cancer screening can be performed both by specially qualified general practitioners and by dermatologists. The skin is systematically examined for suspicious changes. In most cases, this involves a full-body visual examination, sometimes supplemented by dermatoscopy for closer assessment of suspicious lesions. If abnormalities are detected, further diagnostic measures such as biopsies may become necessary (Federal Joint Committee, Cancer Screening Guideline).
2. Why is the benefit of skin cancer screening being questioned?
Because there is still no clear evidence that nationwide screening significantly reduces mortality in the general population (Federal Ministry of Health, 2026; Federal Joint Committee).
3. What does “risk-based skin cancer screening” mean?
It would primarily involve regular examinations of individuals with elevated risk, perhaps those with a family history or fair skin types (Federal Ministry of Health, 2026; Federal Joint Committee).
4. What is the position of many dermatologists regarding the proposed reforms?
Dermatological associations argue that later diagnoses could lead to more severe disease progression and higher treatment costs (Professional Association of German Dermatologists, 2026).
5. When are the changes expected to come into force?
Implementation is planned before the parliamentary summer recess (Deutsches Ärzteblatt, 2026).
Further information on healthcare costs with international comparisons and many other topics can be found on our blog as well as in our book series “Medizinskandale” and “Codex Humanus.” Volume 5 of the latter has recently been published. Feel free to visit our online shop.
Sources:
· Federal Joint Committee (2023): “Evaluation der Screeninguntersuchungen auf Hautkrebs gemäß Krebsfrüherkennungs-Richtlinie. Abschlussbericht 2019–2022.”
· Federal Ministry of Health (2026): “Erster Bericht der FinanzKommission Gesundheit.”
· Federal Ministry of Health (2026): “GKV-Beitragssatzstabilisierungsgesetz – Kabinettsbeschluss vom 29.04.2026.”
· Federal Joint Committee: “Krebsfrüherkennungs-Richtlinie,” continiously updated.
· United States Preventive Services Task Force (2023): “Skin Cancer: Screening,” Recommendation Statement.
· Cancer Research UK: “Screening for melanoma skin cancer,” continuously updated.
· Cancer Council Australia (2019): “Position Statement – Screening and Early Detection of Skin Cancer.”
· Berufsverband der Deutschen Dermatologen (Professional Association of German Dermatologists, 02.04.2026): “Bewährte Früherkennungsuntersuchung soll zu den ersten Leistungskürzungen für GKV-Versicherte zählen.”
· Deutsches Ärzteblatt (13.04.2026): “GKV-Finanz-Gesetz soll am 29. April im Kabinett beschlossen werden.”